TY  - JOUR
T1  - New Topical Therapy for Moderate Psoriasis: An Open-Label, Pilot Study
A1  - José Miguel Ingelmo Calvo
A1  - José Ruiz Cobo
A1  - Mohamed Farouk Allam
JF  - International Journal of Pharmaceutical And Phytopharmacological Research
JO  - Int J Pharm Phytopharmacol Res
SN  - 2250-1029
Y1  - 2024
VL  - 14
IS  - 2
DO  - 10.51847/8b1eX1xZRO
SP  - 31
EP  - 34
N2  - Psoriasis is a persistent, recurring condition characterized by numerous complications. Currently, there is no definitive cure for psoriasis, and treatments typically provide temporary relief of symptoms. Patent 202030824, an innovative cream for psoriasis local treatment, was issued by the Spanish Ministry of Industry, Trade, and Tourism. This product is called "Psorisbye," and it's a foamy lotion that contains clobetasol, propylene glycol, spironolactone, milk-peptide complex, and papaverine hydrochloride. We report on five cases of mild psoriasis that responded well to our recently developed foamy lotion treatment. Our pilot study is an open-label intervention study involving patients with moderate psoriasis. Initially, each patient underwent a comprehensive assessment, encompassing a thorough history-taking and clinical examination. Next, instructions were given to each patient to use our recently developed foamy lotion once a day for a week, using a total of 120 ml of the product during this time. The patients had a follow-up evaluation in the outpatient clinic following a 7-day period of local application. Every patient noted a remission of scaling lesions and claimed a significant reduction in itching sensations. The mean pre-treatment PASI of the patients was 20.28 (SD 6.1), while the mean post-treatment PASI was 1.8. Our preliminary investigation indicated promising results in the treatment of moderate psoriasis with "Psorisbye". Notwithstanding these encouraging results, a longer follow-up is necessary to assess the length of psoriasis remission and any possible adverse effects related to this novel topical medication.
UR  - https://eijppr.com/article/new-topical-therapy-for-moderate-psoriasis-an-open-label-pilot-study-rrp5cpnekgzdr3i
ER  -